Gut Microbiota Market Size

  • Report ID: 3251
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Gut Microbiota Market Size

Gut Microbiota Market size was over USD 770.87 million in 2024 and is anticipated to cross USD 7.56 billion by 2037, growing at more than 19.2% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of gut microbiota is estimated at USD 1.02 billion.

The growth of the market can be attributed to the growing focus on the human immunity system post-COVID-19 as people with low immunity were most affected by the pandemic. According to the World Health Organization as of 23rd March 2023, there have been 761,071,826 confirmed cases of COVID-19 worldwide, which includes 6,879,677 deaths to date. Moreover, the increasing role of gut microbiota in immunity besides the rising research on how to improve gut flora is further expected to boost the market growth.

In addition to these, factors that are believed to fuel the market growth of gut microbiota include soaring investments, and collaboration between major key players to study & develop the human microbiome therapy to the next level. For instance, as per a new Bar-Ilan University study, gut microbes are anticipated to diagnose gestational diabetes as early as the first trimester of pregnancy which is months earlier than typically detected. The rising concern about gestational diabetes mellitus (GDM) worldwide which plagues around 10% of pregnant women across the globe is predicted to present the potential for market expansion over the projected period.


Get more information on this report: Request Free Sample PDF

Browse Key Market Insights with Data Illustration:


Author Credits:  Radhika Pawar


  • Report ID: 3251
  • Published Date: Dec 20, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

In the year 2025, the industry size of gut microbiota is estimated at USD 1.02 billion.

The gut microbiota market size was over USD 770.87 million in 2024 and is anticipated to cross USD 7.56 billion by 2037, growing at more than 19.2% CAGR during the forecast period i.e., between 2025-2037. The increasing focus on gut health and the immunity system post-pandemic as well as the rising prevalence of digestive illness coupled with chronic diseases will boost the market growth.

North America industry is set to hold largest revenue share of 35% by 2037, led by rising concern about digestive illnesses such as gastroesophageal reflux disease (GERD) as well as other lifestyle disorders.

The major players in the market are Merck KGaA, Metabiomics Corporation, ViThera Pharmaceuticals, Inc., Second Genome Inc., Microbiome Therapeutics LLC, Vedanta Biosciences, Inc., Osel, Inc., Synthetic Biologics, Inc., Synlogic, 4D Pharma plc, Metabogen AB, Symbiotix Biotherapies, Inc.
Inquiry Before Buying Request Free Sample
logo
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying
Inquiry Before Buying Request Free Sample